ALK Biomarkers
Amid more tests, drugs, and emerging evidence, commercial insurance coverage for comprehensive genomic profiling remains inconsistent, contributing to access disparities.
LUNGevity Aims for Widespread Comprehensive Biomarker Test Access With New Patient-Facing Campaign
Premium
LUNGevity hopes to streamline patient education messaging and reach lung cancer patients in underserved communities who miss out on comprehensive testing.
Nuvalent Raises $135M in Series B Funding
The company will use the funding to advance its lead NSCLC treatments, a ROS inhibitor and ALK inhibitor, into the clinic.
Turning Point Therapeutics Initiates Phase I/II Trial of TPX-0131 in Lung Cancer
With FDA clearance of its IND, the company has begun studying the drug's dosing and preliminary activity in previously treated, ALK-positive, advanced NSCLC.
FDA Expands Approval of Pfizer's Lorbrena to First-Line ALK-Positive NSCLC; Approves Roche CDx
Based on full approval from the FDA based on the Phase III CROWN trial, Pfizer can now market the drug as a front-line option for ALK-positive NSCLC patients.